Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 24, 2020

Epizyme gets FDA approval for Tazverik to treat epithelioid sarcoma

Epizyme has secured accelerated approval from the US Food and Drug Administration (FDA) for its Tazverik (tazemetostat) to treat pateints epithelioid sarcoma.

The US FDA’s Centre for Drug Evaluation and Research (Credit: The U.S. Food and Drug Administration)